Patents by Inventor Rachel E. Meyers
Rachel E. Meyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090068187Abstract: The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: September 24, 2007Publication date: March 12, 2009Inventors: Maria A. Glucksmann, Rory A.J. Curtis, Fong-Ying Tsai, Martin R. Hodge, Rachel E. Meyers, Kyle J. MacBeth, Rajasekhar Bandaru
-
Patent number: 7485308Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.Type: GrantFiled: July 26, 2006Date of Patent: February 3, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Kyle J. MacBeth, Rory A. J. Curtis, Laura A. Rudolph-Owen, Nadine S. Weich, Peter J. Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph M. Carroll
-
Patent number: 7482147Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 21, 2005Date of Patent: January 27, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John J. Hunter
-
Publication number: 20080311573Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.Type: ApplicationFiled: June 25, 2007Publication date: December 18, 2008Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas SystemInventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai, Funda Meric, Aysegul Sahin, Gordon B. Mills
-
Publication number: 20080241133Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: April 24, 2008Publication date: October 2, 2008Inventors: Rory A. J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
-
Publication number: 20080234468Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 31, 2007Publication date: September 25, 2008Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
-
Patent number: 7411054Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 2, 2006Date of Patent: August 12, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Mark J. Williamson
-
Patent number: 7351566Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 5, 2006Date of Patent: April 1, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
-
Patent number: 7303902Abstract: The invention provides isolated nucleic acids molecules, designated 2150 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2150 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2150 gene has been introduced or disrupted. The invention still further provides isolated 2150 proteins, fusion proteins, antigenic peptides and anti-2150 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 5, 2007Date of Patent: December 4, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Jose M. Lora
-
Patent number: 7301016Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted.Type: GrantFiled: June 27, 2002Date of Patent: November 27, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
-
Patent number: 7282360Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.Type: GrantFiled: December 11, 2006Date of Patent: October 16, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
-
Patent number: 7264926Abstract: The invention provides isolated nucleic acids molecules, designated 39228, 21956, 25856, 22244, 8701, 32263, 50250, 55158, 47765, 62088, 50566, and 48118 nucleic acid molecules, which encode novel GTPase activating molecules, cadherin molecules, and ankyrin containing family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 39228, 21956, 25856, 22244, 8701, 32263, 50250, 55158, 47765, 62088, 50566, and 48118 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 39228, 21956, 25856, 22244, 8701, 32263, 50250, 55158, 47765, 62088, 50566, or 48118 gene has been introduced or disrupted.Type: GrantFiled: May 30, 2002Date of Patent: September 4, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventor: Rachel E. Meyers
-
Patent number: 7256010Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 6, 2005Date of Patent: August 14, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rajasekhar Bandaru, Maria Alexandra Glucksmann, Rachel E. Meyers, Laura A. Rudolph-Owen
-
Patent number: 7211392Abstract: The invention provides isolated nucleic acids molecules, designated 2150 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2150 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2150 gene has been introduced or disrupted. The invention still further provides isolated 2150 proteins, fusion proteins, antigenic peptides and anti-2150 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: April 11, 2005Date of Patent: May 1, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Jose M. Lora
-
Patent number: 7160693Abstract: The invention provides isolated nucleic acids molecules, designated 26443 and 46873 nucleic acid molecules, which encode novel human hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26443 and 46873 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26443 and 46873 gene has been introduced or disrupted. The invention still further provides isolated 26443 and 46873 proteins, fusion proteins, antigenic peptides and anti-26443 or 46873 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 5, 2005Date of Patent: January 9, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventor: Rachel E. Meyers
-
Patent number: 7098015Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 11, 2003Date of Patent: August 29, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
-
Patent number: 7094587Abstract: The invention provides isolated nucleic acids molecules, designated 16002 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16002 gene has been introduced or disrupted. The invention still further provides isolated 16002 proteins, fusion proteins, antigenic peptides and anti-16002 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 18, 2003Date of Patent: August 22, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
-
Patent number: 7078205Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 7, 2002Date of Patent: July 18, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rajasekhar Bandaru, Maria Alexandra Glucksmann, Rachel E. Meyers, Laura A. Rudolph-Owen
-
Patent number: 7070947Abstract: The invention provides isolated nucleic acids molecules, designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.Type: GrantFiled: June 13, 2002Date of Patent: July 4, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
-
Patent number: 7060476Abstract: The present invention relates to a newly identified human PGP synthase. The invention also relates to polynucleotides encoding the PGP synthase. The invention further relates to methods using the PGP synthase polypeptides and polynucleotides as a target for diagnosis and treatment in PGP synthase-mediated or -related disorders. The invention further relates to drug-screening methods using the PGP synthase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the PGP synthase polypeptides and polynucleotides. The invention further relates to procedures for producing the PGP synthase polypeptides and polynucleotides.Type: GrantFiled: August 28, 2002Date of Patent: June 13, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventor: Rachel E. Meyers